Matthew P Morrow Selected Research

VGX-3100

1/2018	Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.
11/2015	Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew P Morrow Research Topics

Disease

9	Infections 01/2018 - 08/2010
8	Neoplasms (Cancer) 01/2021 - 10/2012
5	HIV Infections (HIV Infection) 03/2015 - 10/2006
3	Uterine Cervical Dysplasia 01/2018 - 10/2012
2	Injection Site Reaction 01/2019 - 11/2015
2	Human Influenza (Influenza) 01/2018 - 05/2014
2	Communicable Diseases (Infectious Diseases) 08/2015 - 10/2010
2	Dyslipidemias (Dyslipidemia) 08/2010 - 10/2006
1	COVID-19 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Recurrent respiratory papillomatosis 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2019
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2019
1	Pneumonia (Pneumonitis) 01/2017
1	Weight Loss (Weight Reduction) 01/2016
1	Zika Virus Infection 01/2016
1	Erythema 11/2015
1	Tuberculosis (Tuberculoses) 08/2015
1	Breakthrough Infections 01/2015
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 05/2014
1	Papillomavirus Infections 03/2013
1	Pain (Aches) 10/2012
1	Hepatitis C 12/2011
1	Virus Diseases (Viral Diseases) 10/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 08/2010
1	Tangier Disease 08/2010
1	Atherosclerosis 10/2006
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2006
1	Lipodystrophy 10/2006

Drug/Important Bio-Agent (IBA)

11	VaccinesIBA 01/2022 - 10/2010
6	AntigensIBA 01/2021 - 12/2011
5	DNA VaccinesIBA 01/2018 - 09/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2012
3	Proteins (Proteins, Gene)FDA Link 11/2015 - 03/2009
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 09/2013
2	VGX-3100IBA 01/2018 - 11/2015
2	InterferonsIBA 01/2016 - 10/2012
2	Interleukin-33IBA 08/2015 - 03/2014
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 08/2015 - 03/2014
2	CholesterolIBA 08/2010 - 10/2006
1	PerforinIBA 01/2021
1	Interleukin-12 (IL 12)IBA 01/2021
1	Granzymes (Granzyme)IBA 01/2021
1	AntibodiesIBA 01/2019
1	MEDI0457IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2018
1	Respiratory Syncytial Virus VaccinesIBA 01/2017
1	Formaldehyde (Formol)FDA Link 01/2017
1	CC ChemokinesIBA 01/2015
1	HLA-DR Antigens (HLA-DR)IBA 01/2015
1	Glycoproteins (Glycoprotein)IBA 05/2014
1	Hemagglutinins (Hemagglutinin)IBA 05/2014
1	AlarminsIBA 03/2014
1	Viral AntigensIBA 03/2013
1	EnzymesIBA 10/2012
1	Nucleocapsid ProteinsIBA 09/2011
1	CytokinesIBA 10/2010
1	HDL LipoproteinsIBA 08/2010
1	Adenosine Triphosphate (ATP)IBA 08/2010
1	Pharmaceutical PreparationsIBA 08/2010
1	BenzenesulfonamidesIBA 08/2010
1	Liver X ReceptorsIBA 08/2010
1	LigandsIBA 08/2010
1	vpr Gene ProductsIBA 03/2009
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2006
1	Anti-HIV Agents (AIDS Drugs)IBA 10/2006
1	LipidsIBA 10/2006
1	Lipoproteins (Lipoprotein)IBA 10/2006

Therapy/Procedure

6	Immunotherapy 01/2021 - 03/2013
6	Therapeutics 01/2020 - 08/2010